Fortrea Holdings (FTRE) Revenue (2022 - 2026)
Fortrea Holdings (FTRE) posted Revenue of $636.5 million for Q1 2026, down 3.63% on a QoQ basis from $660.5 million in Q4 2025, and down 2.27% year-over-year from $651.3 million in Q1 2025.
Fortrea Holdings (FTRE) Revenue (2022 - 2026) Analysis & Trends
Fortrea Holdings' Revenue history runs 5 years deep, the most recent figure standing at $636.5 million for Q1 2026.
- Quarterly Revenue fell 2.27% year-over-year to $636.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 0.86% YoY) and the FY2025 annual result came in at $2.7 billion, up 1.0% from the prior year.
- Revenue was $636.5 million for Q1 2026 at Fortrea Holdings, down from $660.5 million in the prior quarter.
- Across five years, Revenue topped out at $793.1 million in Q2 2022 and bottomed at $502.6 million in Q4 2022.
- A 5-year average of $684.8 million and a median of $695.4 million in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2023 — Revenue surged 41.21% — and 2024, when it retreated 8.65%.
- Fortrea Holdings' Revenue stood at $502.6 million in 2022, then jumped by 41.21% to $709.7 million in 2023, then declined by 1.79% to $697.0 million in 2024, then fell by 5.24% to $660.5 million in 2025, then slipped by 3.63% to $636.5 million in 2026.
- Business Quant data shows FTRE's Revenue at $636.5 million in Q1 2026, $660.5 million in Q4 2025, and $701.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | 636.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 636.50 Mn |
| Dec 31, 2025 | 660.50 Mn |
| Sep 30, 2025 | 701.30 Mn |
| Jun 30, 2025 | 710.30 Mn |
| Mar 31, 2025 | 651.30 Mn |
| Dec 31, 2024 | 697.00 Mn |
| Sep 30, 2024 | 674.90 Mn |
| Jun 30, 2024 | 662.40 Mn |
| Mar 31, 2024 | 662.10 Mn |
| Dec 31, 2023 | 709.70 Mn |
| Sep 30, 2023 | 713.80 Mn |
| Jun 30, 2023 | 725.10 Mn |
| Mar 31, 2023 | 693.90 Mn |
| Dec 31, 2022 | 502.60 Mn |
| Sep 30, 2022 | 762.30 Mn |
| Jun 30, 2022 | 793.10 Mn |